32 studies found for:    "Chronic inflammatory demyelinating polyneuropathy"
Show Display Options
Rank Status Study
1 Completed Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: NPB-01
2 Unknown  Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
3 Withdrawn High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Cyclophosphamide
4 Completed
Has Results
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: 10% liquid formulation of human immunoglobulin
5 Completed Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP;   Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: lipoic acid
6 Active, not recruiting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions: Biological: IgPro20;   Biological: Placebo;   Biological: IgPro10
7 Active, not recruiting Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP);   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Biological: IgPro20
8 Completed Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
9 Active, not recruiting Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod;   Drug: Placebo Comparator
10 Recruiting Subcutaneous Immunoglobulin for CIDP
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Immune Globulin Subcutaneous (Human)
11 Recruiting IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Intravenous Immunoglobulin
12 Completed Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
13 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Demyelinating Diseases;   Paraproteinemias
Intervention: Drug: intravenous immunoglobulin (IVIg)
14 Withdrawn Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: H.P. Acthar® Gel
15 Recruiting IVIg for Demyelination in Diabetes Mellitus
Conditions: Peripheral Neuropathy;   Diabetes Mellitus;   Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Drug: 10% intravenous immunoglobulin (IVIg);   Drug: 0.9% sodium chloride
16 Completed Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
17 Enrolling by invitation MRI in Diagnosing and Monitoring CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention:
18 Recruiting Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
19 Recruiting Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
20 Recruiting Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Biological: HYQVIA;   Biological: 0.25% albumin placebo solution with rHuPH20;   Biological: IGIV

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years